Antidiabetic medications and the risk of bladder cancer in patients with diabetes mellitus: A systematic review and meta-analysis
Abstract
Bladder cancer (BC) is the most common malignancy of the urinary system worldwide. Type 2 diabetes mellitus (T2DM) and its treatments may influence BC risk, but existing evidence is conflicting. This study aimed to systematically evaluate the association between various classes of antidiabetic medications (ADMs) and BC risk in patients with T2DM. We conducted a systematic review and meta-analysis following PRISMA guidelines, searching multiple databases up to September 30, 2025. Cohort studies, case-control studies, and randomized controlled trials (RCTs) reporting on ADM use and BC risk were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using fixed- or random-effects models. Heterogeneity, subgroup analyses, and publication bias were assessed. A total of 85 studies were included. The meta-analysis showed that thiazolidinediones (TZDs) use was associated with an increased risk of BC (OR = 1.10, 95% CI: 1.04-1.18), while sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) showed a potential protective effect (OR = 0.81, 95% CI: 0.68-0.97). No significant association was found between BC risk and the use of metformin, sulfonylureas (SUs), insulin, or dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors). Analysis of RCTs for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) also showed no significant effect. Among patients with T2DM, TZDs use may be associated with an increased risk of BC, while SGLT2 inhibitors may be…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.